S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3/PD-L1 pathway
S100A9通过降解PARP1并激活STAT3/PD-L1通路,促进肝细胞癌对PD-1抗体免疫疗法的耐药性。
期刊:Cellular Oncology
影响因子:4.8
doi:10.1007/s13402-025-01087-0
Zhou, Xianwei; Qiao, Chu; Chu, Xuehui; Yang, Yajing; Man, Haoran; Liu, Jingxin; Li, Yunzheng; Xu, Zhu; Li, Huan; Shan, Xiaodong; Lian, Zaowu; Lu, Yanjun; Wang, Weihong; Yu, Decai; Sun, Xitai; Li, Binghua
肿瘤
PARP1
S100A9
肿瘤免疫
JAK/STAT
信号转导
PD-L1
STAT3
PARP
细胞生物学
PD-1
免疫/内分泌